NovaMatrixTM, a business unit of FMC BioPolymer, produces and supplies well-characterized and documented ultrapure bio-compatible and bio-absorbable biopolymers for use in the pharmaceutical, biotechnology and biomedical industries, including applications such as drug delivery, tissue engineering, cell encapsulation, and medical devices. Our products include ultrapure grades of sodium alginate, water-soluble chitosan salts, and sodium hyaluronates that fulfill functional and regulatory requirements.
We manufacture PRONOVATM sodium alginate and PROTASANTM chitosan salts in Sandvika, Norway in accordance with GMP guidelines; ICH Q7; and ISO standards: ISO 9001:2008, ISO 13485:2003 and ISO 22442:2007. Our Sodium Hyaluronate Pharma Grade is produced by our strategic partner, Kikkoman Biochemifa Company (KBC), formerly Kibun Foodchemifa, in Kamogawa, Japan under GMP guidelines; Article 13 of the Pharmaceutical Law of Japan and ISO standards; ISO 9001:2008 and ISO 14001:2004. For these products we maintain drug master files with the US FDA.
NOVATACH peptide-coupled alginates and NOVAFECT oligomeric chitosans are classified as research products as they have not yet been proven to be safe for human use.
In addition to supplying ultrapure biopolymers, NovaMatrix develops applications technology relating to the use of our products and secures the intellectual property rights covering those applications. These rights are typically licensed to customers, often in connection with joint development or R&D agreements. We also will manufacture customized products under development agreements on request.
Our new NovaMatrixTM 3-D cell culture system is based on alginate foam and expands research possibilities in regenerative medicine.